226 related articles for article (PubMed ID: 36781219)
1. Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review.
Choupani E; Mahmoudi Gomari M; Zanganeh S; Nasseri S; Haji-Allahverdipoor K; Rostami N; Hernandez Y; Najafi S; Saraygord-Afshari N; Hosseini A
Pharmacol Rev; 2023 Mar; 75(2):309-327. PubMed ID: 36781219
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
[TBL] [Abstract][Full Text] [Related]
4. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
5. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
[TBL] [Abstract][Full Text] [Related]
8. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.
Christenson JL; O'Neill KI; Williams MM; Spoelstra NS; Jones KL; Trahan GD; Reese J; Van Patten ET; Elias A; Eisner JR; Richer JK
Mol Cancer Ther; 2021 Jun; 20(6):1062-1071. PubMed ID: 33722849
[TBL] [Abstract][Full Text] [Related]
9. Triple negative breast cancer: special histological types and emerging therapeutic methods.
Cao L; Niu Y
Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
[TBL] [Abstract][Full Text] [Related]
10. Ceritinib is a novel triple negative breast cancer therapeutic agent.
Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
[TBL] [Abstract][Full Text] [Related]
11. Chemical degrader enhances the treatment of androgen receptor-positive triple-negative breast cancer.
Wu Y; Xue J; Li J
Arch Biochem Biophys; 2022 May; 721():109194. PubMed ID: 35337811
[TBL] [Abstract][Full Text] [Related]
12. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.
Christenson JL; Trepel JB; Ali HY; Lee S; Eisner JR; Baskin-Bey ES; Elias AD; Richer JK
Horm Cancer; 2018 Apr; 9(2):82-94. PubMed ID: 29340907
[TBL] [Abstract][Full Text] [Related]
13. Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
Sharifi MN; O'Regan RM; Wisinski KB
Clin Breast Cancer; 2023 Dec; 23(8):813-824. PubMed ID: 37419745
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
15. Targeting the androgen receptor in triple-negative breast cancer.
Gucalp A; Traina TA
Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
[TBL] [Abstract][Full Text] [Related]
16. Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer.
Jinna N; Rida P; Smart M; LaBarge M; Jovanovic-Talisman T; Natarajan R; Seewaldt V
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012111
[TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer.
Barton VN; Christenson JL; Gordon MA; Greene LI; Rogers TJ; Butterfield K; Babbs B; Spoelstra NS; D'Amato NC; Elias A; Richer JK
Cancer Res; 2017 Jul; 77(13):3455-3466. PubMed ID: 28512248
[TBL] [Abstract][Full Text] [Related]
18. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
19. The Role of the Androgen Receptor Signaling in Breast Malignancies.
Christopoulos PF; Vlachogiannis NI; Vogkou CT; Koutsilieris M
Anticancer Res; 2017 Dec; 37(12):6533-6540. PubMed ID: 29187427
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
